Navigation Links
Gene Variations Raise the Risk of Childhood Cancer Survivors

Despite surviving the risk of cancer, children were still at the threat of suffering from congestive heart failure due to the complication of the drugs they received during the cancer treatment//.

The researchers studied anthracyclines, a commonly used class of anticancer drugs known to cause heart damage in some patients. The research team investigated two groups of childhood cancer survivors, all of whom had been treated with anthracyclines. The study compared 47 patients with congestive heart failure (CHF) to a control group of 195 patients without CHF.

The researchers investigated 10 polymorphisms, naturally occurring variants in DNA bases called nucleotides, in seven genes they identified as having a role in biological responses to anthracyclines. 'We found that polymorphisms in the GSTP gene significantly increased a patient’s risk for CHF after treatment with anthracyclines,'said Dr. Aplenc. One polymorphism increased risk by five times; another variant was linked to a tripling of risk.

The research group chose particular genes as candidates for study because those genes carry the codes for enzymes involved in metabolizing anthracyclines and the reactive oxygen molecules that anthracyclines produce. If physicians can better classify gene variations that modify side effects of anticancer drugs, they may be able to better tailor treatment plans to individual patients. Thus, knowledge of a patient’s genetic makeup may allow physicians to select a more personalized, less toxic treatment.

'Further study needs to be done, using larger numbers of patients, to determine if these results hold up,' said Dr. Aplenc, a pediatric oncologist at The Children’s Hospital of Philadelphia, 'We hope these findings will provide a scientific foundation for safer, more effective cancer treatments for children.'

Dr. Aplenc’s research abstract was featured in a news conference at the ASCO meeting, which this year has a special focus o n cancer survivors. Dr. Aplenc is an attending oncologist at Children’s Hospital, where he researches gene variations in the enzymes that interact with chemotherapy drugs in children.

(Source: Newswie)

Related medicine news :

1. Variations In ingredients From Brand to Brand
2. Genetic Variations In Detoxifying Genes Lead To Lou Gehrigs diseases
3. Food Costs At Hospitals Show Mystifying Variations
4. Stroke Risk Higher with Gene Variations
5. Ethnic Variations in Hormone Levels May Cause Differences in Breast Cancer Risk
6. Large Variations in Cost Has No Effect on Length of Stay or Mortality
7. Genetic Variations Associated With Risk of Venous Thrombosis Identified
8. Variations of Post–Heart Attack Depression Affect Recover
9. Heavy Drinking Raises Risk of Liver Cancer
10. Swimming in Chlorinated Pools Raises Asthma Risk
11. New Treatment To Raise Good Cholesterol
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: